Neural Regeneration Research ›› 2016, Vol. 11 ›› Issue (8): 1339-1346.doi: 10.4103/1673-5374.189201

Previous Articles     Next Articles

No synergism between bis(propyl)-cognitin and rasagiline on protecting dopaminergic neurons in Parkinson’s disease mice

Cheng-you Zheng1, Bao-jian Guo1, Wei Cai1, Wei Cui2, Shing-hung Mak3, Yu-qiang Wang1, Simon Ming-yuen Lee4, Yi-fan Han3, *, Zai-jun Zhang1, *   

  1. 1 Institute of New Drug Research and Guangzhou Key Laboratory of Innovative Chemical Drug Research in Cardiocerebrovascular Diseases, Jinan University College of Pharmacy, Guangzhou, Guangdong Province, China 2 School of Medicine, Ningbo University, Ningbo, Zhejiang Province, China 3 Department of Applied Biology and Chemical Technology, Institute of Modern Chinese Medicine, The Hong Kong Polytechnic University, Hung Hom, Hong Kong Special Administrative Region, China 4 State Key Laboratory of Quality Research of Chinese Medicine and Institute of Chinese Medical Sciences, University of Macau, Taipa, Macao Special Administrative Region, China
  • Online:2016-08-31 Published:2016-08-31
  • Contact: Zai-jun Zhang, M.D. or Yi-fan Han, zaijunzhang@163.com orbcyfhan@polyu.edu.hk.
  • Supported by:
    This study was supported by grants from the Natural Science Foundation of Guangdong Province of China, No. 2015A030313317; a grant from the Science and Technology Program of Guangzhou City of China, No. 2014J4100097; and partially by a grant from the Science and Technology Development Fund (FDCT) of Macao Special Administrative Region, No. 134/2014/A3; a grant from the Research Committee of University of Macau, No. MYRG139(Y1-L4)-ICMS12-LMY and MYRG2015-00214-ICMS-QRCM; and grants from the Research Grants Council of Hong Kong Special Administrative Region of China, No. 561011, 15101014; the Hong Kong Polytechnic University of China, No. G-SB10, G-UC15 and G-YBGQ

PDF

459

Abstract: Rasagiline, a monoamine oxidase-B inhibitor, and bis(propyl)-cognitin (B3C), a novel dimer are reported to be neuroprotective. Herein, the synergistical neuroprotection produced by rasagiline and B3C was investigated in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced mice of Parkinsonism. By using neurobehavioural tests, high-performance liquid chromatography and western blot assay, we showed that B3C at 0.3 mg/kg, rasagiline at 0.02 mg/kg, as well as co-treatment with B3C and rasagiline prevented MPTP-induced behavioural abnormities, increased the concentrations of dopamine and its metabolites in the striatum, and up-regulated the expression of tyrosine hydroxylase in the substantia nigra. However, the neuroprotective effects of co-treatment were not signifcantly improved when compared with those of B3C or rasagiline alone. Collectively, we have demonstrated that B3C at 0.3 mg/kg and rasagline at 0.02 mg/kg could not produce synergistic neuroprotective effects.

Key words: nerve regeneration, Parkinson’s disease, bis(propyl)-cognitin, rasagiline, monoamine oxidase B, dopamine, multitarget, synergism; neuroprotection, neural regeneration